

Expression of Interest (EOI): Developers and Manufacturers of Ebola tests to support the ongoing outbreak

BACKGROUND

FIND is a global non-profit organization dedicated to accelerating the development, evaluation, and delivery of high-quality, affordable diagnostic tests for poverty-related diseases.

FIND, in collaboration with IPPS and as WHO i-MCM-Net Dx Workstream partner, is exploring opportunities to strengthen diagnostic readiness and response for the ongoing Ebola disease outbreak caused by Bundibugyo virus. Given the urgent need for reliable, deployable, and accessible diagnostics, we are reaching out to diagnostic developers and manufacturers to better understand existing or pipeline technologies that may be relevant for Ebola virus detection, species differentiation, decentralized testing, and outbreak response. IPPS contributes to this effort through its independent tracking and public reporting of the global diagnostic landscape, which this evaluation would feed into at a high level. No confidential information submitted through this EOI will be shared with IPPS.

SCOPE OF EOI

This outreach aims to identify available or near-ready diagnostic solutions, assess their potential suitability for use in affected or at-risk settings, and explore opportunities for collaboration around evaluation, optimization, validation, regulatory pathways, and deployment. The information gathered will help inform a coordinated diagnostic response, support gap assessment, and guide potential partnerships to accelerate access to fit-for-purpose diagnostics for Bundibugyo virus and other priority ebolaviruses.

BENEFITS FOR DEVELOPERS/MANUFACTURERS

Through this engagement, the aim is to complement ongoing country-led and partner-supported response efforts by bringing together technical, market, and implementation expertise to ensure that diagnostics are rapidly identified, assessed, and, where appropriate, advanced for field use.

Your inputs will be critical in providing a better understanding of the current diagnostic landscape, identify promising technologies, and determine where further support or collaboration may be most useful

Applicants with relevant Ebola diagnostic technologies may be contacted to explore the following potential opportunities:

- Listing in the FIND DxConnect Outbreak Test Directory, providing enhanced visibility on Ebola diagnostics development pipeline and available tests: <https://www.finddx.org/tools-and-resources/dxconnect/test-directory/>
- Discussion on projects related to product development/evaluation in the context of diagnostics in LMICs. Submission to this EOI does not imply selection for projects or funding but may inform future targeted Requests for Proposals.

HOW TO PARTICIPATE

To support this process, we would be grateful if you could kindly complete the following survey.

Take the FIND survey: <https://forms.cloud.microsoft/e/EEnjT42P9b>

ELIGIBILITY CRITERIA OF EOI

The following criteria must be met by the developers/manufacturers to respond to this EOI:

- Type of organisations: Original developer / manufacturer of the Ebola test.
- Diagnostic products and technology: Any assays that detect Ebola disease.
- Stage of development: Any.
- Willingness to enter LMIC market.

The following categories of organizations are not in the scope of this EOI:

- Academic teams which lack a development partner or without a clear plan towards commercialization
- Distributors
- Organizations without significant diagnostic R&D and manufacturing in the specified scope (i.e. without any interest in the aforementioned disease / pathogen).

WHO Emergency Use Listing Procedure (EUL) for IVDs

Amid the Public Health Emergency of International Concern (PHEIC) declared on 16 May 2026, an Emergency Use Listing (EUL) procedure for Ebola IVDs has recently been launched by WHO.

Interested parties can find further details and respond to this WHO initiative here:

<https://extranet.who.int/prequal/vitro-diagnostics/bundibugyo-virus-disease-pheic-emergency-use-listing-procedure-eul-ivds>

CONFIDENTIALITY

FIND acknowledges that the information received from Applicants under the EOI may be of a confidential nature. FIND shall use the same degree of care with Applicant's confidential information as it uses to protect its own confidential information. If required, FIND can sign a CDA with interested Applicants prior to proposal submission. FIND will communicate the confidential information only to its employees, independent contractors, institutional donors and other financial sponsors, legal, financial, scientific or technical advisors (together "Representatives") who: (a) need to know such confidential information for FIND's internal purposes, and (b) such Representative has previously agreed in writing to be bound by terms and conditions substantially similar to those contained in this EOI, including but not limited to confidentiality and non-use restrictions. Review of proposals will be carried out by an internal FIND team as well as a team of external experts (which may or may not include members of FIND's independent Scientific Advisory Committee), all of whom are under confidentiality and are recused if found to have a potential conflict of interest (which they are obliged to disclose). Any specific questions concerning confidentiality should be addressed to the FIND team.